

1 **Title:** Impact of SARS-CoV-2 on Seasonal Respiratory Viruses: A Tale of Two Large
2 Metropolitan Centers in the United States

3
4 **Authors:** Amy C. Sherman^{1,2}, Ahmed Babiker^{1,3}, Andrew J. Sieben⁴, Alexander Pyden⁵, James
5 Steinberg¹, Colleen S. Kraft^{1,3}, Katia Koelle⁶, Sanjat Kanjilal^{2,7}.

6 **Affiliations:**

- 7
8 1- Division of Infectious Diseases, Department of Medicine, Emory University School of
9 Medicine, Atlanta, GA.
10 2- Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA
11 3- Department of Pathology and Laboratory Medicine, Emory University School of
12 Medicine, Atlanta, GA
13 4- Emory University School of Medicine, Atlanta, GA
14 5- Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA
15 6- Department of Biology, Emory University, Atlanta, GA
16 7- Department of Population Medicine, Harvard Medical School and Harvard Pilgrim
17 Healthcare Institute, Boston, MA
18
19
20
21

22 Running Title: Impact of SARS-CoV-2 on Seasonal Viruses

23
24 Key words: SARS-CoV-2, influenza, RSV, transmission, epidemiology

25
26 **Corresponding Author:** Amy C. Sherman, acs Sherman@bwh.harvard.edu, Division of
27 Infectious Diseases, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115

28
29 **Alternative Corresponding Author:** Ahmed Babiker, ahmed.babiker@emory.edu, Division of
30 Infectious Diseases, Emory University School of Medicine, 101 Woodruff Cir, WMB 2309-A,
31 Atlanta, GA 30322.
32

33 **Abstract**

34 To assess the impact of the SARS-CoV-2 pandemic on seasonal respiratory viruses, absolute
35 case counts and viral reproductive rates from 2019-2020 were compared against previous
36 seasons. Our findings suggest that the public health measures implemented to reduce SARS-
37 CoV-2 transmission significantly reduced the transmission of other respiratory viruses.

38

39 The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has
40 resulted in over 7.4 million cases of coronavirus disease 2019 (COVID-19) and over 210,000
41 deaths in the United States alone, as of October 7, 2020 [1]. The introduction of SARS-CoV-2
42 into the northern hemisphere in January 2020 overlapped with the peak circulation of seasonal
43 respiratory viruses that include influenza A and B and respiratory syncytial virus (RSV). Like
44 SARS-CoV-2, these viruses are also spread primarily through droplet and contact transmission
45 routes, with concern that co-circulating respiratory pandemics could further stress our healthcare
46 systems and economy [2, 3].

47 The danger represented by the unchecked spread of SARS-CoV-2 prompted a massive
48 rollout of population-level non-pharmaceutical interventions (NPIs) to curb transmission,
49 including stay-at-home orders, the closure of schools and retail spaces, mandated face masks in
50 public, and encouragement of social distancing and hand hygiene. Studies from Hong Kong,
51 France, Japan, Singapore and Australia have shown these measures have also coincided with a
52 decline in the number of cases of the seasonal respiratory viruses over the same time period, as
53 compared to prior seasons [3-7]. A similar trend occurred in the U.S., with the number of people
54 with influenza-like illness (ILI) [8] for the 2019-2020 season decreasing earlier than expected as
55 compared to the 2015-2016, 2008-2009, and 2002-2003 influenza seasons [9].

56 In this study, we sought to define the impact of NPIs intended to curb SARS-CoV-2
57 transmission on the rates of infection from influenza A, influenza B and RSV in two large U.S
58 academic centers located in Atlanta, Georgia and Boston, Massachusetts from January through
59 May 2020. The heterologous impact of NPIs has important implications for clinicians and
60 laboratories preparing for future respiratory virus seasons.

61 We conducted a retrospective review of medical records for all inpatient and outpatient
62 adults who underwent testing for respiratory viruses over the previous 5 seasons (09/01/2015 –
63 05/30/2020), at the Emory Healthcare system (EHC) and associated clinics in Atlanta (n =46,575
64 people) and the Mass General Brigham (MGB) Healthcare System in Boston (n = 107,260
65 people). Each respiratory virus season was defined as beginning on September 01 (week 36) of a
66 given year and extending through May 30 (week 22) of the following year. The weeks were
67 assigned according to the International Organization for Standardization (ISO) week date
68 standard, which defines the start and end of a week on Monday and Sunday, respectively.
69 Specimens were obtained using nasopharyngeal swabs and tested by the eSensor® Respiratory
70 Viral Panel (GenMark Diagnostics, Inc., Carlsbad, CA) at EHC and the Cepheid Xpert or the
71 Hologic Panther Fusion at MGB, per manufacturer instructions. A small subset of patients at
72 MGB and EHC were tested for SARS-CoV-2 using oropharyngeal swabs and lower respiratory
73 tract samples. Total cases of influenza A and B, RSV, and SARS-CoV-2 were calculated for
74 each week of each season. These case counts were then used to calculate the pathogen-specific
75 reproductive number over time, R_t , given by the ratio of the number of new positive cases in one
76 week to the number of positive cases in the previous week. A reproductive number greater than
77 1.0 corresponds to an increase in the number of cases between two consecutive weeks, whereas a
78 value between zero and 1.0 corresponds to a decrease.

79 To evaluate the impact of NPIs, we compared the R_t for influenza A, influenza B, and
80 RSV averaged over all previous seasons to the current season (2019-2020) using a bootstrapping
81 approach. Specifically, we first drew randomly from a binomial distribution to generate absolute
82 counts for each virus, for each week of each season. The binomial distributions were
83 parameterized using the number of tests in a given week as the number of trials and the percent

84 of tests positive for the virus as the success probability. Once values of absolute counts were
85 drawn, the bootstrapped R_t value for that pair of consecutive weeks was generated by taking the
86 ratio of the counts in one week to the counts in the previous week. This procedure was repeated
87 to generate 1,000 independent samples. Mean R_t values were calculated for a given pair of
88 consecutive weeks by averaging over a set of four R_t values drawn from the bootstrapped
89 samples, representing one value from each of the previous four seasons (2015-2016 through
90 2018-2019). Similarly, 95% CIs were calculated from the distribution of R_t values generated by
91 the bootstrapped samples for each week of each season. We utilized only the first positive test
92 for each patient, to reduce bias introduced by patients with persistently positive tests. For the
93 2019-2020 season, mean R_t values and 95% CI were calculated. All analyses were conducted
94 using R (v 4.0.0).

95 For influenza A infections in Atlanta, the effective reproductive number R_t dropped
96 below 1.0 on week 12 of the 2019-2010 season, whereas in previous seasons the effective
97 reproductive number did not consistently drop below 1.0 prior to week 15 (Figure 1). This
98 decrease in influenza A cases coincides with the first detection of SARS-CoV-2 cases in Atlanta,
99 which began in week 11, and coincides with the city of Atlanta restricting large gatherings,
100 closing bars, and issuing a stay-at-home order (weeks 12-13). Case counts for influenza B fell to
101 near zero cases per week after week 13, precluding the calculation of reproductive numbers. In
102 prior years, R_t values decreased to <1.0 after week 15, which shows that rates of influenza B
103 infections decreased earlier in the 2019-2020 season relative to past seasons. In Atlanta, RSV R_t
104 values did not drop below 1.0 until week 13 during the current season and week 14 for previous
105 seasons (Supplemental Figure 1).

106 Similar trends were observed in Boston (Figure 1). For influenza A infections in Boston,
107 the effective reproductive number R_t dipped below 1.0 on week 7 and fell to 0 at week 14 of the
108 2019-2020 season. The effective R_t for influenza A in previous seasons did not remain below 1.0
109 before week 15. For influenza B, R_t was consistently below 1.0 at week 11 while the R_t of
110 influenza B in past seasons did not consistently drop below 1.0 before week 15. In Boston,
111 social gatherings were restricted to 25 people or less on week 11, and stay-at-home advisories
112 were issued on week 13, which corresponds to the decrease of influenza A and B cases. For
113 RSV, R_t predominantly fell below 1.0 from weeks 12-15 for the 2019-2020 season while
114 previous seasons' R_t values remained above 1.0.

115 The implementation of NPIs was a critical factor in reducing the spread of SARS-CoV-2
116 globally. We provide evidence from two geographically distinct metropolitan U.S. cities that
117 NPIs may also have exerted a collateral beneficial effect on influenza A and B and RSV by
118 virtue of reducing opportunities for transmission. Although the overall case counts of SARS-
119 CoV-2 and the response to the pandemic differed in Atlanta and Boston, the results demonstrate
120 the importance of social distancing measures. These findings should help inform pre- and post-
121 test probabilities when evaluating patients presenting with symptoms consistent with an upper or
122 lower respiratory tract viral syndrome, as well as the interpretation of respiratory virus panel
123 testing performed for asymptomatic screening purposes.

124 The dynamics of influenza, RSV, and SARS-CoV-2 epidemiology are complex, and the
125 interplay between these respiratory viruses will become increasingly important to dissect as a
126 new influenza season emerges in the fall of 2020. Globally, the effects of decreased influenza
127 cases from January to May 2020, due to either decreased transmission or decreased surveillance,
128 may confound the ability to accurately predict which strains will be circulating in the fall. With

129 decreased international travel and border restrictions, there may also be a change in the temporal
130 dynamics of influenza illness in 2020-2021, and the circulating strains may differ from those
131 predicted in February 2020. Further study is warranted to determine the downstream effects that
132 SARS-CoV-2 will have on influenza transmission and epidemiological trends.

133 Limitations which must be acknowledged include the possibility of decreased reporting
134 of influenza and RSV in March due to a decline in overall outpatient clinic visits (Supplemental
135 Figure 2, total influenza and RSV tests conducted), preservation of viral media and equipment
136 for SARS-CoV-2 testing, and transitions in hospitals to prioritize SARS-CoV-2 testing over
137 other viral diagnostics for hospitalized patients [10]. Complex viral factors and dynamics
138 between circulating SARS-CoV-2 and influenza viruses may have also influenced this trend.
139 The phenomenon of respiratory virus “interference” has been described for epidemics of
140 influenza and other respiratory viruses, in which one epidemic delays the start or accelerates the
141 end of the other viral epidemic [11-13]. The underlying immune mechanisms for virus
142 interference are not well elucidated but may be due to temporary non-specific immunity for a
143 given acute respiratory infection [14].

144 In summary, the data demonstrate that NPIs are likely effective in reducing both
145 influenza and SARS-CoV-2 transmission. Concurrent epidemics of influenza and SARS-CoV-2
146 have the potential to result in diagnostic confusion, and significant morbidity and mortality and
147 could overwhelm the healthcare system. Consequently, NPIs, in addition to widespread
148 utilization and uptake of influenza vaccination, will be important public health tools to deploy to
149 mitigate the threat of these respiratory viruses. Ongoing diagnostic and surveillance efforts for
150 influenza, RSV and SARS-CoV-2 must be maintained to further explore the transmission
151 mechanisms and interplay between these respiratory viruses.

152 **Conflict of Interest**

153 The authors report no conflict of interest.

154

155 **Funding**

156 No funding to report.

157

158 **Acknowledgments**

159 We would like to acknowledge our laboratory colleagues at the Emory University Healthcare
160 and Mass General Brigham Healthcare System Microbiology and Molecular laboratories and
161 who have worked tirelessly to provide necessary care to our patients during this time.

162

163 **Figure Legends**

164

165 **Figure 1:** Cases per week of influenza A and B and SARS-CoV-2 of seasons 2015-2020 in the
166 MGB Healthcare systems in Boston (**panel A**) and in the Emory University in Atlanta (**panel B**)
167 by week of respiratory virus season (note the change in y-axis scale for Boston SARS-CoV-2
168 cases, panel A). Comparison of the reproductive number over time, R_t , for influenza A and B in
169 prior seasons (the average of the 2015-2016 through 2018-2019 seasons, as depicted by the black
170 line) versus the 2019-2020 season as depicted by the red line, for Boston (**panel C**) and Atlanta
171 (**panel D**). The black dotted horizontal line denotes R_t of 1.0. The red dotted vertical line
172 represents the approximate date when NPIs were initiated in Atlanta and Boston (week 13).

173

174 **Supplemental Figure 1:** Cases per week of RSV of seasons 2015-2020 in the MGB Healthcare
175 systems in Boston (**panel A**) and in the Emory University in Atlanta (**panel B**) by week of
176 respiratory virus season. Comparison of the reproductive number over time, R_t , for RSV in prior
177 seasons (the average of the 2015-2016 through 2018-2019 seasons, as depicted by the black line)
178 versus the 2019-2020 season as depicted by the red line, for Boston (**panel C**) and Atlanta
179 (**panel D**). The black dotted horizontal line denotes R_t of 1.0. The red dotted vertical line
180 represents the approximate date when NPIs were initiated in Atlanta and Boston (week 13).

181
182 **Supplemental Figure 2:** Total tests conducted for influenza A and B combined for seasons
183 2015-2020 in the MGB Healthcare systems in Boston (**panel A**) and in the Emory University in
184 Atlanta (**panel B**) by week of respiratory virus season.

185

186 REFERENCES

187

- 188 1. CDC. Coronavirus Diseases 2019 (COVID-19) - Cases and Latest Updates. Available at:
189 <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html>. Accessed
190 03/18/2020.
- 191 2. Klompas M, Baker MA, Rhee C. Airborne Transmission of SARS-CoV-2: Theoretical
192 Considerations and Available Evidence. *Jama* **2020**.
- 193 3. Yeoh DK, Foley DA, Minney-Smith CA, et al. The impact of COVID-19 public health
194 measures on detections of influenza and respiratory syncytial virus in children during the
195 2020 Australian winter. *Clin Infect Dis* **2020**.

- 196 4. Cowling BJ, Ali ST, Ng TWY, et al. Impact assessment of non-pharmaceutical
197 interventions against coronavirus disease 2019 and influenza in Hong Kong: an
198 observational study. *The Lancet Public health* **2020**; 5(5): e279-e88.
- 199 5. Boëlle PY, Souty C, Launay T, et al. Excess cases of influenza-like illnesses synchronous
200 with coronavirus disease (COVID-19) epidemic, France, March 2020. *Euro surveillance :*
201 *bulletin Europeen sur les maladies transmissibles = European communicable disease*
202 *bulletin* **2020**; 25(14).
- 203 6. Sakamoto H, Ishikane M, Ueda P. Seasonal Influenza Activity During the SARS-CoV-2
204 Outbreak in Japan. *Jama* **2020**; 323(19): 1969-71.
- 205 7. Soo RJJ, Chiew CJ, Ma S, Pung R, Lee V. Decreased Influenza Incidence under COVID-
206 19 Control Measures, Singapore. *Emerg Infect Dis* **2020**; 26(8): 1933-5.
- 207 8. CDC. Weekly U.S. Influenza Surveillance Report. Accessed 10th August 2020.
- 208 9. Zipfel CM, Bansal S. Assessing the interactions between COVID-19 and influenza in the
209 United States. *medRxiv* **2020**: 2020.03.30.20047993.
- 210 10. Babiker A, Myers CW, Hill CE, Guarner J. SARS-CoV-2 Testing: Trials and
211 Tribulations. *American Journal of Clinical Pathology* **2020**.
- 212 11. Anestad G. Interference between outbreaks of respiratory syncytial virus and influenza
213 virus infection. *Lancet (London, England)* **1982**; 1(8270): 502.
- 214 12. Chan KF, Carolan LA, Korenkov D, et al. Investigating Viral Interference Between
215 Influenza A Virus and Human Respiratory Syncytial Virus in a Ferret Model of Infection.
216 *J Infect Dis* **2018**; 218(3): 406-17.

- 217 13. Price OH, Sullivan SG, Sutterby C, Druce J, Carville KS. Using routine testing data to
218 understand circulation patterns of influenza A, respiratory syncytial virus and other
219 respiratory viruses in Victoria, Australia. *Epidemiology and infection* **2019**; 147: e221.
- 220 14. Feng S, Fowlkes AL, Steffens A, Finelli L, Cowling BJ. Assessment of Virus
221 Interference in a Test-negative Study of Influenza Vaccine Effectiveness. *Epidemiology*
222 (Cambridge, Mass) **2017**; 28(4): 514-24.
- 223






Figure 1: Cases per week of influenza A and B and SARS-CoV-2 of seasons 2015-2020 in the MGB Healthcare systems in Boston (**panel A**) and in the Emory University in Atlanta (**panel B**) by week of respiratory virus season. Note the change in y-axis scale for Boston SARS-CoV-2 cases (**panel A**). Comparison of the reproductive number over time, R_t , for influenza A and B in prior seasons (the average of the 2015-2016 through 2018-2019 seasons, as depicted by the black line) versus the 2019-2020 season as depicted by the red line, for Boston (**panel C**) and Atlanta (**panel D**). The black dotted horizontal line denotes R_t of 1.0. The red dotted vertical line represent the approximate date when NPIs were initiated in Atlanta and Boston (week 13).



Supplemental Figure 1: Cases per week of RSV of seasons 2015-2020 in the MGB Healthcare systems in Boston (**panel A**) and in the Emory University in Atlanta (**panel B**) by week of respiratory virus season. Comparison of the reproductive number over time, R_t , for RSV in prior seasons (the average of the 2015-2016 through 2018-2019 seasons, as depicted by the black line) versus the 2019-2020 season as depicted by the red line, for Boston (**panel C**) and Atlanta (**panel D**). The black dotted horizontal line denotes R_t of 1.0. The red dotted vertical line represent the approximate date when NPIs were initiated in Atlanta and Boston (week 13).



Supplemental Figure 2: Total tests conducted for influenza A and B combined for seasons 2015-2020 in the MGB Healthcare systems in Boston (**panel A**) and in the Emory University in Atlanta (**panel B**) by week of respiratory virus season.